Advertisement
UK markets closed
  • FTSE 100

    8,285.71
    +99.36 (+1.21%)
     
  • FTSE 250

    21,356.30
    +471.95 (+2.26%)
     
  • AIM

    779.67
    +6.64 (+0.86%)
     
  • GBP/EUR

    1.1844
    -0.0006 (-0.05%)
     
  • GBP/USD

    1.2873
    +0.0019 (+0.14%)
     
  • Bitcoin GBP

    52,964.59
    +694.34 (+1.33%)
     
  • CMC Crypto 200

    1,379.01
    +48.40 (+3.64%)
     
  • S&P 500

    5,459.10
    +59.88 (+1.11%)
     
  • DOW

    40,589.34
    +654.27 (+1.64%)
     
  • CRUDE OIL

    76.44
    -1.84 (-2.35%)
     
  • GOLD FUTURES

    2,385.70
    +32.20 (+1.37%)
     
  • NIKKEI 225

    37,667.41
    -202.10 (-0.53%)
     
  • HANG SENG

    17,021.31
    +16.34 (+0.10%)
     
  • DAX

    18,417.55
    +118.83 (+0.65%)
     
  • CAC 40

    7,517.68
    +90.66 (+1.22%)
     

Ultimovacs ASA: Invitation to first quarter 2023 results webcast presentation

Ultimovacs ASA
Ultimovacs ASA

Oslo, 3 May 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its first quarter 2023 results on Wednesday 10 May 2023.

The presentation can be followed as a live webcast accessed through a link on www.ultimovacs.com at 14:00 CET on Wednesday 10 May 2023. The webcast presentation will be available on the Ultimovacs website, and it will be possible to post questions during the presentation through the webcast.

The report and presentation will be available on the company website from 08:00 CET the same day.

ADVERTISEMENT

For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507

Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632

Anne Worsøe, Head of Investor Relations
Email: anne.worsoe@ultimovacs.com
Phone: +47 906 86815